Martin J. Edelman

Dr. Edelman received his Bachelor of Science and medical degree in 1982 as part of the Rensselaer Polytechnic Institute/Albany Medical College 6 year combined BS/MD program and performed his internship and residency in Internal Medicine and Fellowship in Hematology and Oncology at the Naval Medical Center San Diego. After leaving active military service, Dr. Edelman joined the faculty at the University of California, Davis 1990, where he was co-leader of the thoracic oncology program with Dr. David Gandara. In 1999, he left UC Davis and went to the University of Maryland Greenebaum Cancer Center. He has been active in the US National Clinical Trials Network as the medical oncology co-chair for the Lung Cancer Committee and a member of the ECOG Lung Cancer Committee and was previously with CALGB and SWOG.

Dr. Edelman is a member of the Thoracic Malignancies Steering Committee of the NCI. He has also served as the Chair of the Integration Panel for the DOD Congressionally Mandated Research Program for lung cancer, a member of the NIH subcommittee H, the ASCO program, education and governmental affairs committees and several NIH study sections. He is a past Chair of the Ethics Committee and the Career Development Committee and a member of the Communications Committee of the IASLC and a Deputy Editor of the journal “Lung Cancer”. Dr. Edelman was appointed as Chair of the Scientific Advisory Board for the Lung Cancer Foundation of America in February 2018. He has published over 180 peer reviewed papers in the field. In February 2017, he moved to Fox Chase Cancer Center to become the G. Morris Dorrance Professor and Chair of the Department of Hematology/Oncology and Deputy Director for Clinical Research. He completed his Naval service with the rank of Captain (ret), USNR in 2004.

Dr. Edelman developed one of the most commonly utilized regimens for the treatment of advanced lung cancer in the 1990’s. He initiated some of the earliest studies to evaluate treatment regimens in lung cancer based upon biomarkers. He led the first randomized study in the U.S. cooperative group system (now the National Clinical Trials Network) to evaluate a drug based upon a specific biomarker. In addition, he has led studies. At Fox Chase he continues to work on trials to develop novel agents and approaches for the treatment of lung cancer and other thoracic malignancies. His work has been funded by the National Cancer Institute, philanthropic foundations and industry. He was recently awarded a grant from the Department of Defense to evaluate a new approach to lung cancer screening. In addition to his work on anticancer therapies, he has done research and published on issues of supportive care for the cancer patients, follow-up strategies and outcomes.